242 related articles for article (PubMed ID: 30136072)
1. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.
Pastoriza JM; Karagiannis GS; Lin J; Lanjewar S; Entenberg D; Condeelis JS; Sparano JA; Xue X; Rohan TE; Oktay MH
Clin Exp Metastasis; 2018 Oct; 35(7):613-623. PubMed ID: 30136072
[TBL] [Abstract][Full Text] [Related]
2. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
Kim G; Pastoriza JM; Qin J; Lin J; Karagiannis GS; Condeelis JS; Yothers G; Anderson S; Julian T; Entenberg D; Rohan TE; Xue X; Sparano JA; Oktay MH
Cancer; 2022 Jul; 128(14):2728-2735. PubMed ID: 35578919
[TBL] [Abstract][Full Text] [Related]
3. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
[TBL] [Abstract][Full Text] [Related]
4. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
[TBL] [Abstract][Full Text] [Related]
5. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
[TBL] [Abstract][Full Text] [Related]
6. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer.
Howard-McNatt M; Lawrence J; Melin SA; Levine EA; Shen P; Stewart JH
Am J Surg; 2013 Apr; 205(4):397-401. PubMed ID: 23422317
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
9. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
10. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
Huang J; Zhang JL; Ang L; Li MC; Zhao M; Wang Y; Wu Q
Front Endocrinol (Lausanne); 2023; 14():1265520. PubMed ID: 37900131
[TBL] [Abstract][Full Text] [Related]
11. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
Bagegni NA; Tao Y; Ademuyiwa FO
PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
[TBL] [Abstract][Full Text] [Related]
14. Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
Benefield HC; Allott EH; Reeder-Hayes KE; Perou CM; Carey LA; Geradts J; Sun X; Calhoun BC; Troester MA
J Natl Cancer Inst; 2020 Jul; 112(7):728-736. PubMed ID: 31742342
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.
Johnson KC; Grimm M; Sukumar J; Schnell PM; Park KU; Stover DG; Jhawar SR; Gatti-Mays M; Wesolowski R; Williams N; Sardesai S; Pariser A; Sudheendra P; Tozbikian G; Ramaswamy B; Doto D; Cherian MA
Breast; 2023 Dec; 72():103591. PubMed ID: 37871527
[TBL] [Abstract][Full Text] [Related]
16. Does race predict survival for women with invasive breast cancer?
Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
[TBL] [Abstract][Full Text] [Related]
17. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
18. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer.
Park YR; Lee J; Jung JH; Kim WW; Park CS; Lee RK; Chae YS; Lee SJ; Park JY; Park JY; Park HY
Asian J Surg; 2020 Mar; 43(3):467-475. PubMed ID: 31204155
[TBL] [Abstract][Full Text] [Related]
19. Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapy.
Kim G; Karadal-Ferrena B; Qin J; Sharma VP; Oktay IS; Lin Y; Ye X; Asiry S; Pastoriza JM; Cheng E; Ladak N; Condeelis JS; Adler E; Ginter PS; D'Alfonso T; Entenberg D; Xue X; Sparano JA; Oktay MH
NPJ Breast Cancer; 2023 Jun; 9(1):52. PubMed ID: 37311792
[TBL] [Abstract][Full Text] [Related]
20. Refining the indications for neoadjuvant chemotherapy for patients with HER2+ breast cancer: A single institution experience.
Pomponio MK; Burkbauer L; Goldbach M; Nazarian SM; Xie F; Clark AS; Matro JM; Fox KR; Shulman LN; Keele LJ; Tchou J
J Surg Oncol; 2020 Mar; 121(3):447-455. PubMed ID: 31919848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]